Acute Biphenotypic Leukemia (ABL) Recruiting Phase 2 Trials for Enasidenib (DB13874)

Also known as: Acute biphenotypic leukaemia / Acute Biphenotypic Leukemia / Leukemia, Biphenotypic, Acute / Acute bilineal leukemia

IndicationStatusPhase
DBCOND0081399 (Acute Biphenotypic Leukemia (ABL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03683433Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationTreatment